SPECIALTY TOPICS · GUIDE
Classic Psychedelics: What the Term Covers
Content last updated . This page has not been medically reviewed.
Back to Psychedelic TherapyWhat the term covers
"Classic psychedelics" is a pharmacology term, not a cultural one. [2] A 2016 pharmacology review reports a consensus that these drugs are agonists or partial agonists at brain serotonin 2A receptors. [3]An "agonist" is a substance that switches a receptor on. A receptor is a docking point on a brain cell. The page Serotonin Receptors in Plain Language explains what this does and does not tell us.
The four named examples
Each example has a different origin, which is one reason the word "classic" should not be read as "natural" or "traditional".| Substance | Origin as described in sources |
|---|---|
| Psilocybin | Comes from certain types of mushrooms found on nearly every continent. [4] |
| DMT | Found in the leaves of the Psychotria viridis bush, one of the two plants in the Amazonian brew ayahuasca. [6] |
| Mescaline | A naturally occurring alkaloid found in cacti, mainly peyote and cacti of the Echinopsis genus. [7] |
DMT and ayahuasca are not the same thing: see DMT vs Ayahuasca.
What they are reported to do
NIDA reports that people using these drugs describe vivid visions or sensations, a changed sense of self, and feelings ranging from intense happiness and connection to fear, anxiety and confusion. [2] NIDA says studies suggest the most prominent effects stem from activity in the prefrontal cortex and that these drugs temporarily disrupt communication between brain regions, including the default mode network. [2] How much that matters for any health benefit is a separate question, covered in Proposed Mechanisms vs Proven Clinical Outcomes.What "classic" does not mean
- Not "safe". NIDA says effects vary widely and can include fear, anxiety and dangerous behavior, and that there is some evidence these drugs might trigger a schizophrenia-like illness in people with predisposing factors. [2]
- Not "the same drug". The four examples differ in origin, chemistry and the research behind them. See Why Different Substances Cannot Be Treated as Equivalent.
Evidence labels on this page
This page makes classification statements, not treatment claims. Where it touches approval it uses the label approved medicine (a regulator has approved a product for a stated use) only for what the regulator has actually approved. Treatment evidence for specific conditions is on the pages for major depressive disorder and PTSD. The full list of labels is in how we label evidence.Education only
This guide describes categories. It gives no amounts, no sourcing or preparation information and no advice to use or to treat yourself.Frequently asked questions
Are classic psychedelics all natural?
No. [4][7][5]
Do classic psychedelics all act only on 5-HT2A receptors?
No. Mescaline, for example, is reported to act at 5-HT2A and 5-HT2C receptors and also at noradrenaline and dopamine receptors, and DMT is described as a 5-HT1A/2A partial agonist. [7][6]
Are classic psychedelics approved to treat anything?
According to NIDA's page read 2026-10-22, no classic psychedelic is FDA approved for therapeutic use; two psilocybin formulations have Breakthrough Therapy designation for study in depression. [8]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Safety note
References
- US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355. Read 2026-10-22 (abstract on PubMed).
- National Institute on Drug Abuse, Psilocybin (Magic Mushrooms). Read 2026-10-22.
- Dos Santos RG, Hallak JEC. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024;30(1):e2. Read 2026-10-22 (abstract on PubMed).
- Vamvakopoulou IA et al. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. Read 2026-10-22 (abstract on PubMed).
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs as Medicines. Read 2026-10-22.